+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hereditary Testing Market - Global Forecast 2026-2032- Product Image
Hereditary Testing Market - Global Forecast 2026-2032- Product Image
Sale

Hereditary Testing Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5306608
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hereditary Testing Market is projected to reach USD 19.65 Billion in 2026. It is expected to continue growing at a CAGR of 13.90%, reaching USD 43.23 Billion by 2032.

Hereditary testing is moving from specialty genetics into mainstream precision medicine as next-generation sequencing, expanded carrier screening, hereditary cancer panels, pharmacogenomics, and whole-exome or whole-genome sequencing become more accessible to clinicians and patients. The category focuses on germline variants that can inform disease risk, diagnosis, treatment selection, reproductive planning, and cascade testing for relatives.

Demand is supported by established clinical utility in hereditary breast and ovarian cancer, Lynch syndrome, familial hypercholesterolemia, cardiomyopathies, rare pediatric disorders, and prenatal or preconception screening. Public resources such as ClinVar, ClinGen, and gnomAD, along with professional guidance from organizations including ACMG, AMP, NCCN, and ESHG, have strengthened evidence interpretation, while privacy, informed consent, genetic counseling access, and equitable testing pathways remain central to responsible industry development.

Transformative Shifts in Hereditary Testing

The hereditary testing landscape is shifting from single-gene assays toward multi-gene panels and broader sequencing approaches that can shorten diagnostic odysseys and improve risk stratification. Health systems are increasingly embedding genetic counselors, molecular tumor boards, electronic health record integration, and digital consent workflows into care pathways to manage test selection, patient education, and results disclosure.

Regulatory modernization is also reshaping commercialization. In the United States, the FDA’s 2024 final rule on laboratory-developed tests introduced a phased approach to oversight, while Europe’s In Vitro Diagnostic Regulation has raised expectations for clinical evidence, quality management, performance evaluation, and post-market surveillance. These changes favor laboratories and technology providers that can demonstrate analytical validity, clinical validity, interoperability, secure data governance, and transparent variant interpretation practices.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating hereditary testing by improving variant prioritization, phenotype matching, report drafting, literature surveillance, and variant reclassification workflows. AI-enabled systems can help laboratories triage variants of uncertain significance by integrating population frequency, evolutionary conservation, predicted protein impact, segregation evidence, functional data, and curated knowledgebases.

The impact is cumulative rather than instantaneous. Breakthrough models such as AlphaMissense, reported in 2023 to predict the effects of millions of possible missense variants, illustrate the scale of computational support available to genetics. However, clinical use still requires independent validation, transparent performance monitoring, human expert review, bias assessment, and alignment with ACMG/AMP variant interpretation standards to avoid automation bias, misclassification risk, and health inequity.

Key Regional Insights

North America remains one of the most mature regions for hereditary testing, led by broad payer coverage discussions, established reference laboratory infrastructure, high oncology adoption, active clinical guidelines, and expanding use of genetics in preventive care. Canada’s provincial health systems support targeted access to hereditary cancer, rare disease, and reproductive genetics services, although reimbursement pathways, turnaround times, and test availability vary by province.

Europe benefits from national genomics programs, strong academic networks, and GDPR-driven data protection, with the United Kingdom, Germany, France, Italy, and Spain advancing sequencing in rare disease, cancer predisposition, and clinical genomics. Asia-Pacific is scaling rapidly through Japan’s advanced clinical infrastructure, Australia’s genomics networks, South Korea’s precision medicine ecosystem, and expanding sequencing capacity in China and India, where large populations and cost-sensitive diagnostic models are influencing access strategies. Latin America, led by Brazil and Mexico, shows growing oncology and reproductive genetics demand but faces persistent gaps in reimbursement, trained genetics professionals, and decentralized access. The Middle East, particularly GCC countries, emphasizes premarital screening, carrier testing, newborn screening, and national genome initiatives, while Africa presents long-term potential as sequencing infrastructure, workforce training, biobanking, and population-specific reference data improve.

Key Group Insights

ASEAN markets are heterogeneous, with Singapore and Thailand showing stronger precision medicine readiness, while Indonesia, Vietnam, the Philippines, and Malaysia continue expanding specialist capacity, laboratory networks, and referral pathways. The GCC is highly relevant because national genomics programs, premarital screening policies, and higher prevalence of inherited recessive disorders in some populations create a clear public health rationale for hereditary testing and cascade screening.

The European Union is shaping the industry through IVDR compliance, cross-border research, the 1+ Million Genomes initiative, and emerging health data space policies that support secure genomic data use. BRICS countries provide scale and diversity, with China and India influencing test accessibility and cost innovation, Brazil expanding regional leadership in oncology and rare disease genetics, and Russia and South Africa contributing specialized clinical and research capacity. G7 countries drive premium reimbursement expectations, evidence standards, rare disease policy, and companion diagnostics adoption, while NATO countries increasingly view secure genomic infrastructure, data protection, and resilient diagnostic supply chains as part of broader health security preparedness.

Key Country Insights

The United States leads in commercial laboratory scale, hereditary cancer testing, pharmacogenomics pilots, newborn and rare disease genomics, and patient access innovation, though payer coverage rules and genetic counseling capacity remain uneven. Canada continues to build province-led access models, Mexico is expanding private-sector genetic services and oncology-focused testing, and Brazil is the primary Latin American growth engine for hereditary cancer, reproductive genetics, and rare disease diagnostics.

In Europe, the United Kingdom’s Genomic Medicine Service, Germany’s strong diagnostics sector, France’s national genomic medicine agenda, and expanding programs in Italy and Spain support clinical adoption, while Russia maintains specialized genetics capabilities under a distinct regulatory environment. In Asia-Pacific, China’s sequencing capacity, India’s large patient base and cost-sensitive diagnostics market, Japan’s advanced medical system, Australia’s national genomics networks, and South Korea’s digital health strengths collectively define regional momentum across hereditary cancer, carrier screening, rare disease diagnosis, and precision medicine integration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize hereditary testing services with clear clinical utility, guideline alignment, and payer-relevant outcomes, particularly hereditary cancer, cardiovascular genetics, rare disease diagnosis, reproductive carrier screening, and pharmacogenomics. Commercial strategies should include evidence dossiers, health economic models, and measurable clinical endpoints such as earlier diagnosis, avoided procedures, targeted surveillance, optimized therapy selection, or family cascade testing uptake.

Operationally, organizations should invest in genetic counseling partnerships, variant curation teams, secure data architecture, multilingual patient education, culturally appropriate consent processes, and recontact policies for variant reclassification. AI should be deployed as decision support with audit trails and quality controls, not as a replacement for board-certified molecular review. Leaders should also strengthen interoperability with electronic health records and build reimbursement strategies around clinically actionable results.

Research Methodology

This executive summary is based on secondary research from publicly available, authoritative sources including regulatory agencies, professional medical guidelines, peer-reviewed genomics literature, public variant databases, national genomics programs, clinical policy statements, and health system documentation. The analysis emphasizes validated clinical applications of hereditary testing rather than speculative consumer genetics claims.

Market interpretation applies triangulation across clinical adoption indicators, reimbursement signals, regulatory developments, population health initiatives, laboratory quality requirements, and technology trends. Regional, group, and country insights reflect observable healthcare infrastructure, policy direction, sequencing capacity, genetic services maturity, workforce availability, and data governance frameworks. No market sizing, market share, or forecasting assumptions are included.

Conclusion

Hereditary testing is becoming a foundational component of precision medicine as sequencing costs decline, evidence standards mature, and healthcare systems recognize the value of prevention, early diagnosis, reproductive planning, and family-based risk management. The strongest opportunities are in clinically actionable use cases supported by professional guidelines, reimbursement logic, genetic counseling infrastructure, and rigorous laboratory quality systems.

The next phase of industry development will be defined by responsible AI, equitable access, regulatory compliance, secure genomic data governance, and stronger integration of genetic results into routine care. Organizations that combine scientific credibility with scalable workflows and patient-centered implementation will be best positioned to support adoption across oncology, rare disease, cardiovascular genetics, reproductive health, and pharmacogenomics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hereditary Testing Market, by Testing Type
7.1. Introduction
7.2. Direct Gene Mutation Tests
7.2.1. Single-gene Tests
7.2.2. Multi-gene Panel Tests
7.3. Whole Genome Sequencing
7.4. Whole Exome Sequencing
7.5. Mitochondrial DNA Testing
7.6. Chromosomal Microarray Analysis
8. Hereditary Testing Market, by Sample Type
8.1. Introduction
8.2. Blood
8.3. Saliva
8.4. Buccal swab
8.5. Amniotic fluid
9. Hereditary Testing Market, by Technology Platform
9.1. Introduction
9.2. Next-Generation Sequencing
9.3. Polymerase Chain Reaction (PCR)-based methods
9.4. Sanger Sequencing
9.5. Microarray-based tests
10. Hereditary Testing Market, by Application
10.1. Introduction
10.2. Cardiovascular Hereditary Testing
10.2.1. Cardiomyopathies
10.2.2. Arrhythmias
10.3. Oncology
10.4. Rare Diseases
10.5. Reproductive Health
10.6. Hematologic Hereditary Testing
10.7. Metabolic & Storage Disorders
11. Hereditary Testing Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Hospitals & Clinics
11.4. Research Institutes
11.5. Pharmacogenomics Labs
11.6. Reproductive Health Centers
12. Hereditary Testing Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Hereditary Testing Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Hereditary Testing Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Agilent Technologies Inc.
16.3. Ambry Genetics Corporation
16.4. Ancestry.com LLC
16.5. ARUP Laboratories Inc.
16.6. Becton Dickinson and Company
16.7. BGI Genomics Co Ltd.
16.8. Bio-Rad Laboratories Inc.
16.9. Blueprint Genetics Oy
16.10. Caris Life Sciences Inc.
16.11. Centogene NV
16.12. Color Health Inc.
16.13. Danaher Corporation
16.14. Eurofins Scientific SE
16.15. Exact Sciences Corporation
16.16. Foundation Medicine Inc.
16.17. Fulgent Genetics Inc
16.18. GeneDx Holdings Corp
16.19. Guardant Health Inc.
16.20. Illumina Inc.
16.21. Invitae Corporation
16.22. Labcorp Holdings Inc.
16.23. Myriad Genetics Inc.
16.24. Natera Inc.
16.25. Oxford Nanopore Technologies plc
16.26. QIAGEN NV
16.27. Quest Diagnostics Incorporated
List of Figures
FIGURE 1. GLOBAL HEREDITARY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEREDITARY TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEREDITARY TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEREDITARY TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HEREDITARY TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DIRECT GENE MUTATION TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DIRECT GENE MUTATION TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DIRECT GENE MUTATION TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL SINGLE-GENE TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL SINGLE-GENE TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL SINGLE-GENE TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MULTI-GENE PANEL TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MULTI-GENE PANEL TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MULTI-GENE PANEL TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MITOCHONDRIAL DNA TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MITOCHONDRIAL DNA TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MITOCHONDRIAL DNA TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CHROMOSOMAL MICROARRAY ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CHROMOSOMAL MICROARRAY ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CHROMOSOMAL MICROARRAY ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL BUCCAL SWAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL BUCCAL SWAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BUCCAL SWAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL AMNIOTIC FLUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL AMNIOTIC FLUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL AMNIOTIC FLUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL POLYMERASE CHAIN REACTION (PCR)-BASED METHODS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL POLYMERASE CHAIN REACTION (PCR)-BASED METHODS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL POLYMERASE CHAIN REACTION (PCR)-BASED METHODS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SANGER SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SANGER SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SANGER SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MICROARRAY-BASED TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MICROARRAY-BASED TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL MICROARRAY-BASED TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CARDIOVASCULAR HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CARDIOVASCULAR HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CARDIOVASCULAR HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CARDIOMYOPATHIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CARDIOMYOPATHIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CARDIOMYOPATHIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ARRHYTHMIAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ARRHYTHMIAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ARRHYTHMIAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL REPRODUCTIVE HEALTH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL REPRODUCTIVE HEALTH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL REPRODUCTIVE HEALTH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HEMATOLOGIC HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HEMATOLOGIC HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HEMATOLOGIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL METABOLIC & STORAGE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL METABOLIC & STORAGE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL METABOLIC & STORAGE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PHARMACOGENOMICS LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PHARMACOGENOMICS LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PHARMACOGENOMICS LABS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL REPRODUCTIVE HEALTH CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL REPRODUCTIVE HEALTH CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL REPRODUCTIVE HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. EUROPE HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 105. EUROPE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 106. EUROPE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 107. EUROPE HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 108. EUROPE HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. AFRICA HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. AFRICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 127. AFRICA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 128. AFRICA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 129. AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 130. AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. AFRICA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 132. AFRICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. NATO HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. NATO HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 144. NATO HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 145. NATO HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 146. NATO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 147. NATO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 148. NATO HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 149. NATO HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. G7 HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. G7 HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 152. G7 HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 153. G7 HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 154. G7 HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 155. G7 HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 156. G7 HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 157. G7 HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. BRICS HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. BRICS HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 160. BRICS HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 161. BRICS HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 162. BRICS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 163. BRICS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 164. BRICS HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 165. BRICS HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. ASEAN HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. ASEAN HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 176. ASEAN HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 177. ASEAN HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 178. ASEAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 179. ASEAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 180. ASEAN HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 181. ASEAN HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. GCC HEREDITARY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. GCC HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 184. GCC HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 185. GCC HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 186. GCC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 187. GCC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. GCC HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 189. GCC HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 191. CHINA HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. CHINA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 193. CHINA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 194. CHINA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 195. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 196. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 197. CHINA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 198. CHINA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. JAPAN HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. JAPAN HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 209. JAPAN HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 210. JAPAN HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 211. JAPAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 212. JAPAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 213. JAPAN HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 214. JAPAN HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. INDIA HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. INDIA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 217. INDIA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 218. INDIA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 219. INDIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 220. INDIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 221. INDIA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 222. INDIA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GERMANY HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. GERMANY HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 225. GERMANY HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 226. GERMANY HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 227. GERMANY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 228. GERMANY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 229. GERMANY HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 230. GERMANY HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 243. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 244. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 245. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 246. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. FRANCE HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. FRANCE HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 249. FRANCE HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 250. FRANCE HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 251. FRANCE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 252. FRANCE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. FRANCE HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 254. FRANCE HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 257. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 258. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 260. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 261. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. ITALY HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. ITALY HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 265. ITALY HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 266. ITALY HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 267. ITALY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 268. ITALY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 269. ITALY HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 270. ITALY HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. CANADA HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. CANADA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 273. CANADA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 274. CANADA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 275. CANADA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 276. CANADA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. CANADA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 278. CANADA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. BRAZIL HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 289. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 290. BRAZIL HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 291. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 292. BRAZIL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 293. BRAZIL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 294. BRAZIL HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. MEXICO HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. MEXICO HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 297. MEXICO HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 298. MEXICO HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 299. MEXICO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 300. MEXICO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 301. MEXICO HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 302. MEXICO HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. SPAIN HEREDITARY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. SPAIN HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 305. SPAIN HEREDITARY TESTING MARKET SIZE, BY DIRECT GENE MUTATION TESTS, 2017-2032 (USD MILLION)
TABLE 306. SPAIN HEREDITARY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 307. SPAIN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 308. SPAIN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 309. SPAIN HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR HEREDITARY TESTING, 2017-2032 (USD MILLION)
TABLE 310. SPAIN HEREDITARY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. GLOBAL HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 312. GLOBAL HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Ambry Genetics Corporation
  • Ancestry.com LLC
  • ARUP Laboratories Inc.
  • Becton Dickinson and Company
  • BGI Genomics Co Ltd.
  • Bio-Rad Laboratories Inc.
  • Blueprint Genetics Oy
  • Caris Life Sciences Inc.
  • Centogene NV
  • Color Health Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • Foundation Medicine Inc.
  • Fulgent Genetics Inc
  • GeneDx Holdings Corp
  • Guardant Health Inc.
  • Illumina Inc.
  • Invitae Corporation
  • Labcorp Holdings Inc.
  • Myriad Genetics Inc.
  • Natera Inc.
  • Oxford Nanopore Technologies plc
  • QIAGEN NV
  • Quest Diagnostics Incorporated

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.65 Billion
Forecasted Market Value ( USD ) by 2032 $ 43.23 Billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Hereditary Testing - Global Strategic Business Report - Product Image

Hereditary Testing - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Hereditary Testing Market Size, Share & Trends Analysis Report by Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), Technology (Cytogenetic, Biochemical, Molecular Testing) and Region with Growth Forecasts, 2025-2033 - Product Image

Hereditary Testing Market Size, Share & Trends Analysis Report by Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), Technology (Cytogenetic, Biochemical, Molecular Testing) and Region with Growth Forecasts, 2025-2033

  • Report
  • 270 Pages
  • Global
From
Hereditary Testing Market Report 2026 - Product Image

Hereditary Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Hereditary Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Hereditary Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 182 Pages
  • Global
From
Hereditary Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type (Diagnostic Testing, Predictive & Presymptomatic Testing, Carrier Screening, Prenatal & Newborn Testing, Pharmacogenomic Testing), Offering, Technology, Application - Product Image

Hereditary Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type (Diagnostic Testing, Predictive & Presymptomatic Testing, Carrier Screening, Prenatal & Newborn Testing, Pharmacogenomic Testing), Offering, Technology, Application

  • Report
  • 160 Pages
  • Global
From

About the Hereditary Testing Market

The Hereditary Testing market within the context of Diagnostics is a rapidly growing field of medical research. It involves the use of genetic testing to identify inherited diseases and conditions, as well as to assess the risk of developing certain diseases. This type of testing can be used to diagnose a wide range of conditions, including cancer, heart disease, and neurological disorders. It can also be used to identify genetic mutations that may be associated with certain diseases. Hereditary testing is becoming increasingly popular as a way to identify and manage inherited diseases. It is also being used to identify genetic markers that may be associated with certain diseases, such as Alzheimer's and Parkinson's. This type of testing can provide valuable information to help guide treatment decisions and improve patient outcomes. Some of the companies in the Hereditary Testing market include 23andMe, AncestryDNA, MyHeritage, and Helix. These companies offer a variety of services, including genetic testing, ancestry testing, and health-related services. They also provide access to a wide range of genetic data, which can be used to identify inherited diseases and conditions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.